News and Trends 2 Jun 2022
Upstream Bio to target asthma as it launches with $200M financing
Upstream Bio, a U.S. biotech company focused on inflammation, today exited stealth mode with $200M Series A financing. The company said the funding will allow it to advance its lead program UPB-101, a clinical-stage monoclonal antibody targeting the thymic stromal lymphopoietin (TSLP) receptor. It added the investment will also help build a pipeline of assets […]